Expression of the p56lck by colon tumors: A marker of their invasive capacity?;Expression de la p56lck par les tumeurs du côlon: Un marqueur de leur potentiel invasif?

Bulletin du Cancer

Volumn 91, Issue 12, 2004, Pages 928-940

  Rouer, Evelyne ^a  

^a INSERM   (France)

Author keywords

Colon cancer; Metastase; p56lck

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROTEIN KINASE LCK; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

CANCER INVASION; CELL ADHESION; COLON CANCER; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; LCK GENE; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; ONCOGENE; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW;

COLONIC NEOPLASMS; GENE DELETION; GENE EXPRESSION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); LYMPHOCYTES; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS PP60(C-SRC);

EID: 12844273401     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Abraham N, Miceli MC, Parnes JR, Veillette A. Enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck. Nature 1991; 350: 62-6.
2. Kabouridis PS, Magee AI, Ley SC. S-acylation of Lck protein tyrosine kinase is essential for its signaling function in T lymphocytes. EMBO J 1997; 16: 4983-98.
3. Turner JM, Brodsky HM, Irving BA, Levin SD, Perlmutter RM, Littman DR. Interaction of the unique N-terminal region of tyrosine kinase p56lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs. Cell 1990; 60: 755-65.
4. Dustin ML, Cooper JA. The immunological synapse and actin cytoskeleton: molecular hardware for T cell signalling. Nat Immunol 2000; 1: 23-9.
5. Montixi C, Langlet C, Bernard AM, et al. Engagement of T-cell receptor triggers its recruitment to low-density detergent-insoluble membrane domains. EMBO J 1998; 17: 5334-48.
6. Drevot P, Langlet C, Guo XJ, et al. TCR signal initiation machinery is pre-assembled and activated in a subset of membrane rafts. EMBO J 2002; 21: 1899-908.
7. Shade AE, Levine AD. Lipid raft heterogeneity in human peripheral blood T lymphoblasts: a mechanism for regulating the initiation of TCR signal transduction. J Immunol 2002; 168: 2233-9.
8. Xavier R, Brennan T, Qingqin L, McCormack C, Seed B. Membrane compartmentation is required for efficient T cell activation. Immunity 1998; 8: 723-32.
9. Bergman M, Mustelin T, Oatken C, et al. The human p50csk tyrosine kinase phosphorylates p56lck at Tyr505 and down regulates its catalytic activity. EMBO J 1992; 11: 2919-24.
10. Ostergaard HL, Shackelford DA, Hurley TR, et al. Expression of CD45 alters phosphorylation of the lck-encoded tyrosine kinase in murine lymphoma T-cell lines. Proc Natl Acad Sci USA 1989; 86: 8959-63.
11. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structure of c-Src reveals features of its autoinhibitory mechanism. Mol Cell 1999; 3: 629-30.
12. Kabouridis PS. Selective interaction of LAT (linker of activated T cells) with the open-active form of Lck in lipid rafts reveals a new mechanism for the regulation of Lck in T cells. Biochem J 2003; 371: 907-15.
13. Gupta S, Weiss A, Kumar G, Wang S, Nel A. The T-cell antigen receptor utilizes Lck, Raf-1 and MEK-1 for activating mitogen-activated protein kinase. J Biol Chem 1994; 269: 17349-57.
14. Molina TJ, Kishihara K, Siderovski DP, et al. Profound block in thymocyte development in mice lacking p56lck. Nature 1992; 357: 161-4.
15. Gacon G, Gisselbrecht S, Piau JP, Boissel JP, Tolle J, Fischer S. High level of tyrosine protein kinase in a murine lymphoma cell line induced by Moloney leukaemia virus. EMBO J 1982; 1: 1579-82.
16. Rouer E, Huynh TV, Lavareda de Souza S, Lang MC, Fischer S, Benarous R. Structure of the human lck gene: differences in genomic organisation within src-related genes affect only N-terminal exons. Gene 1989; 84: 105-13.
17. Wildin RS, Garvin AM, Pawar S, et al. Developmental regulation of lck gene in T-lymphocytes. J Exp Med 1991; 173: 383-93.
18. Rouer E, Dreyfus F, Melle J, Benarous R. Pattern of expression of five alternative transcripts of the lck gene in hematopoietic malignacies: correlation of the level of lck mRNA IB with the immature phenotype of the malignancy. Cell Growth Differ 1994; 5: 659-66.
19. Tycko B, Smith SD, Sklar J. Chromosomal translocations joining Lck and TcR B loci in human T cell leukaemia. J Exp Med 1991; 174: 867-73.
20. Rouer E, Dreyfus F, Melle J, Ribrag V, Benarous R. Selective increase of alternatively spliced lck transcripts from the proximal promoter in hematopoietic malignancies. Leukemia 1993; 7: 246-50.
21. Marth JD, Disteche C, Pravtcheva D, Ruddle F, Krebs EG, Perlmutter RM. Localisation of a lymphocyte-specific protein tyrosine kinase gene (lck) at a site of frequent chromosomal anormalities in human lymphomas. Proc Natl Sci USA 1986; 83: 7400-4.
22. Goldman FD, Ballas ZK, Schutte BC, et al. Defective expression of p56lck in an infant with severe combined immunodeficiency. J Clin Invest 1998; 102: 421-9.
23. Germani A, Malherbe S, Rouer E. The exon-7 spliced Lck isoform in T lymphocytes: a potential regulator of p56lck signaling pathways. Biochem Biophys Res Com 2003; 301: 680-5.
24. Van Drenth C, Jenkins A, Ledwich L, et al. Desensitization of CXC chemokine receptor 4, mediated by IL-16/CD4, is independent of p56lck enzymatic activity. J Immunol 2000; 165: 6356-63.
25. Gisselbrecht S. Oncogenes et leucemies: historique et perspectives. Med Sciences 2003; 19: 201-10.
26. Veillette A, Foss FM, Sausville EA, Bolen JB, Rosen N. Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene Res 1987; 1: 357-74.
27. McCracken S, Kim CS, Xu Y, Minden M, Miyamoto NG. An alternative pathway for expression of p56lck from type 1 promoter transcripts in colon carcinoma. Oncogene 1997; 15: 2929-37.
28. Leung S, Miyamoto NG. Differential expression of two classes of lck transcripts upon phorbol ester treatment of human leukemic T cells. J Cell Physiol 1991; 148: 344-52.
29. Nakamura K, Chijiiwa Y, Nawata H. Augmented expression of lck message directed from the downstream promoter in human colorectal cancer specimens. Eur J Cancer 1996; 32A: 1401-7.
30. Mayer K, Ballhausen WG. Expression of alternatively spliced lck transcripts from the proximal promoter in colorectal cancer derived cell lines. Anticancer Res 1996; 16: 1733-7.
31. Allen JM, Forbush KA, Perlmutter RM. Functional dissection of the lck proximal promoter. Mol Cell Biol 1992; 12: 2758-68.
32. Yamada A, Takaki S, Hayashi F, Georgopoulos K, Perlmutter RM, Takatsu K. Identification and characterization of a transcriptional regulator for the lck proximal promoter. J Biol Chem 2001; 276: 18082-9.
33. Muise-Helmericks RC, Rosen N. Identification of a novel repressive element in the proximal lck promoter. J Biol Chem 1995; 270: 27538-43.
34. Lo K, Landau NR, Smale ST. LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. Mol Cell Biol 1991; 11: 5229-43.
35. Leung S, McCracken S, Ghysdael J, Miyamoto NG. Requirement of an ETS-binding element for transcription of the human lck type I promoter. Oncogens 1993; 8: 989-97.
36. McCracken S, Leung S, Bosselut R, Ghysdael J, Miyamoto NG. Myb and related transcription factors are required for activity of the human lck type 1 promoter. Oncogene 1994; 9: 3609-15.
37. Mayer K, Hieronymus T, Castrop J, Clevers H, Ballhausen WG. Ectopic activation of lymphoid high mobility group-box transcription factor TCF-1 and overexpression in colorectal cancer cells. Int J Cancer 1997; 72: 625-30.
38. Pongracz J, Hare K, Harman B, Anderson G, Jenkinson EJ. Thymic epithelial cells provide Wnt signals to developing thymocytes. Eur J Immunol 2003; 33: 1949-56.
39. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275: 1784-7.
40. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signalling in colon cancer by mutations in β-catenin or APC. Science 1997; 275: 1787-90.
41. Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-6.
42. Korinek V, Barker N, Moerer P, et al. Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nature Genet 1998; 19: 379-83.
43. Bonneton C, Larue L, Thierry JP. Données recentes sur le rôle de la protéine APC dans la genèse du cancer colorectal. Bull Cancer 1997; 84: 1053-60.
44. Sherman L, Wainwright D, Ponta H, Herlich P. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev 1998; 12: 1058-71.
45. Nestl A, Von Stein OD, Zatloukal K, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 2001; 61: 1569-77.
46. Xu Y, Yu Q. E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis. J Biol Chem 2003; 278: 8661-8.
47. Thorne RF, Legg JW, Isacke CM. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Science 2004; 117: 373-80.
48. Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R. The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings and mutational analysis in colorectal cancer cell lines. Cancer Res 2000; 60: 3872-9.
49. Roose J, Huls G, Van Beest M, et al. Synergy between tumor suppressor APC and the β-catenin-Tcf-4 target tcf-1. Science 1999; 285: 1923-6.
50. Frixen U, Behrens J, Sachs ME, et al. E-cadherin mediated cell-cell adhesion prevent invasiveness of human carcinoma cell lines. J Cell Biol 1991; 117: 173-85.
51. Conacci-Sorrel M, Simcha I, Ben-Yedidia T, Blechman J, Savager P, Ben-Zeev A. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of β-catenin signalling, Slug and MAPK. J Cell Biol 2003; 163: 847-57.
52. Volberg T, Zick Y, Dror R, et al. The effect of tyrosine-specific protein phosphorylation in the assembly of adherens-type junctions. EMBO J 1992; 11: 1733-42.
53. Tsukita S, Oishi K, Akiyama T, Yamanashi Y, Yamamoto T, Tsukita S. Specific proto-oncogenic tyrosine kinases of Src family are enriched in cell-to-cell adherens junctions where the level of tyrosine phosphorylation is elevated. J Cell Biol 1991; 113: 867-79.
54. Matsuyoshi N, Hamaguchi M, Taniguchi S, Nagafuchi A, Tsukita S, Takeichi M. Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol 1992; 118: 703-14.
55. Roura S, Miravet S, Piedra J, Garcia de herreros A, Dunach M. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 1999; 274: 36734-40.
56. Müller T, Choidas A, Reichmann E, Ullrich A. Phosphorylation and free pool of β-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem 1999; 274: 10173-83.
57. Boyer B, Roche S, Denoyelle M, Thiery JP. Src and Ras are involved in separate pathways in epithelial cell scattering. EMBO J 1997; 16: 5904-13.
58. Maher PA. Disruption of cell-substrate adhesion activates the protein tyrosine kinase pp60c-src. Exp Cell Res 2000; 260: 189-98.
59. Mahabeleshwar GH, Kundu GC. Tyrosine kinase p56lck regulates cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of Iκβα following hypoxia/reoxygenation. J Biol Chem 2003; 278: 52598-612.
60. Briant L, Robert-Hebmann V, Acquaviva C, Pelchen-Mattews A, Marsh M, Devaux C. The protein tyrosine kinase p56lck is required for triggering NFκB activation upon interaction of human immunodeficiency virus type I envelope glycoprotein gp120 with cell surface CD4. J Virol 1998; 72: 6207-14.
61. Nakamura K, Hori T, Saro N, Sugie K, Kawakami T, Yodoi J. Redox regulation of a src family protein tyrosine kinase p56lck in T cells. Oncogene 1993; 8: 3133-9.
62. Hardwick JS, Sefton BM. Activation of the Lck tyrosine protein kinase by hydrogen peroxide requires the phosphorylation of Tyr 394. Proc Natl Acad Sci USA 1995; 92: 4527-31.
63. Mahabeleshwar GH, Das R, Kundu GC. Tyrosine kinase p56lck-induced cell motility and urokinase type plasminogen activator secretion involves activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways. J Biol Chem 2003; 278: 52598-612.
64. Maa MC, Leu T-H, McCarley DJ, Schatzman RC, Parsons SJ. Potentiation of epidermal growth factor receptor-mediaded oncogenesis by c-src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 1995; 92: 6981-5.
65. Krystal GW, DeBerry CS, Linnekin D, Litz J. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1. Cancer Res 1998; 58: 4660-6.
66. Brenner B, Gulbins E, Schlottmann K, et al. L-selectin activates the Ras pathway via the tyrosine kinase p56lck. Proc Natl Acad Sci USA 1996; 93: 15376-81.
67. Giglione C, Gonfloni S, Parmeggiani A. Differential actions of p60c-Src and Lck kinases on the Ras regulators p120-GAP and GDP/GTP exchange factor CD25Mm. Eur J Biochem 2001; 268: 3275-83.
68. Inngjerdingen M, Torgensen KM, Maghazachi AA. Lck is required for stromal cell-derived factor 1α (CXCL12)-induced lymphoid cell chemotaxis. Blood 2002; 99: 43186-225.
69. Feigelson SW, Grabovsky V, Winter E, et al. The src kinase p56lck upregulates VLA-4 integrin affinity. J Biol chem 2001; 276: 13891-901.
70. Fagerholm S, Hilden TJ, Gahmberg CG. Lck tyrosine kinase is important for activation of the CD11a/CD18 integrins in human T lymphocytes. Eur J Immunol 2002; 32: 1670-8.
71. Sharma CP, Ezzell RM, Arnaout MA. Direct interaction of filamin (ABP-280) with the 2-integrin subunit CD18. J Immunol 1995; 154: 3461-70.
72. Goldmann WH. Phosphorylation of filamin (ABP-280) regulates the binding to the lipid membrane, integrin and actin. Cell Biol Intern 2001; 25: 805-8.
73. Forster-horvath C, Bocsi J, Raso E, et al. Constitutive intracellular expression and activation-induced cell surface up-regulation of CD44v3 in human T lymphocytes. Eur J Immunol 2001; 31: 600-8.
74. Akisik E, Bavbek S, Dalay N. CD44 variant exons in leukaemia and lymphoma. Pathol Oncol Res 2002; 8: 36-40.
75. Taher TI, Smit L, Griffioen AW, Schilder-Tol EJM. Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes. J Biol Chem 1996; 271: 2863-7.
76. Llangumaran S, Briol A, Hoessli DC. CD44 selectively associates with active src family protein tyrosine kinases Lck and Fyn in glycosphingolipid-rich plasma membrane domains of human peripheral blood lymphocytes. Blood 1998; 9: 3901-8.
77. Li R, Wong N, Jabali MD, Johnson P. CD44-initiated cell spreading induces Pyk2 phosphorylation, is mediated by Src family kinases, and is negatively regulated by CD45. J Biol Chem 2001; 276: 28767-73.
78. Legg JW, Lewis CA, Parsons M, Ng T, Isacke CM. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nature Cell Biol 2002; 4: 399-407.
79. Abraham KM, Levin SD, Marth JD, Forbush A, Perlmutter RM. Thymic tumorigenesis induced by overexpression of p56lck. Proc Natl Acad Sci USA 1991; 88: 3977-81.
80. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colonrectal mucosa and cancer. Cancer Res 1998; 58: 5489-94.
81. Chen H, Zhang Z, Zhang YL, Zhou DY. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res 1999; 19: 3675-80.
82. Hur YG, Yun Y, Won J. Rosmarinic acid induces p56lck-dependent apoptosis in jurkat and peripheral T cells via mitochondrial pathway independent from Fas/Fas ligand interaction. J Immunol 2004; 172: 79-87.
83. Ait Si Ali S, Guasconi V, Harel-bellan A. Inhibition de l'expression génique par l'ARN interérence: applications dans le domaine du cancer. Bull Cancer 2004; 91: 15-8.